Fig. 1.
Cumulative incidence of CNS progression (a) in all eligible patients (n = 279); b patients without cerebral metastasis prior to EGFR-TKIs first-line treatment; c patients cerebral metastasis prior to EGFR-TKIs first-line treatment
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.